Therapeutic strategies based on immunological hypotheses of Alzheimer's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 54, 1998, Pages 175-186

  Moller H J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROPENTOFYLLINE; NEUROPROTECTIVE AGENT; XANTHINE DERIVATIVE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COGNITION; DEMENTIA; DRUG EFFECT; HIGH RISK POPULATION; HUMAN; IMMUNOPATHOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; AGED; BIOLOGICAL MODEL; CONTROLLED CLINICAL TRIAL; FEMALE; IMMUNOLOGY; MALE;

AGED; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONTROLLED CLINICAL TRIALS; FEMALE; HUMANS; INDOMETHACIN; MALE; MODELS, IMMUNOLOGICAL; NEUROPROTECTIVE AGENTS; XANTHINES;

EID: 0031593607     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-7508-8_17     Document Type: Review

References (28)

1. Banati RB, Schubert P, Rothe G, Gehrmann J, Rudolphi K, Valet G, Kreutzberg GW (1994) Modulation of intracellular formation of reactive oxygen intermediates in peritoneal macrophages and microglia/brain macrophages by propentofylline. J Cereb Blood Flow Metab 14: 145-149
2. Bauer J, Strauss S, Schreiter Gasser U, Ganter U, Schlegel P, Witt I, Yolk B, Berger M (1991) Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett 285: 111-114
3. Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, Anthony JC (1994) Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 44: 227-232
4. 2 blocking drugs. Neurobiol Aging 16: 523-530
5. Breteler MM, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, Jorm AF, Kokmen E, Kondo K, Mortimer JA, et al (1991) Medical history and the risk of Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 20 [Suppl 2]: S36-42
6. Broe GA, Henderson AS, Creasey H, McCusker E, Korten AE, Jorm AF, Longley W, Anthony JC (1990) A case-control study of Alzheimer's disease in Australia. Neurology 40: 1698-1707
7. Eikelenboom P, Hack CE, Rozemuller JM, Stam FC (1989) Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol 56: 259-262
8. Fiebich BL, Lieb K, Hull M, Berger M, Bauer J (1996) Effects of NSAIDs on IL-1 beta-induced IL-6 mRNA and protein synthesis in human astrocytoma cells. Neuroreport 7: 1209-1213
9. French LR, Schuman LM, Mortimer JA, Hutton JT, Boatman RA, Christians B (1985) A case-control study of dementia of the Alzheimer type. Am J Epidemiol 121: 414-421
10. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, Araoz C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86: 7611-7615
11. Henderson AS, Jorm AF, Korte AE, Creasey H, McCusker E, Broe GA, Longley W, Antony JC (1992) Environmental risk factors for Alzheimer's disease: their relationship to age of onset and to familial or sporadic types. Psychol Med 22: 429-436
12. Huell M, Strauss S, Volk B, Berger M, Bauer J (1995) Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients. Acta Neuropathol (Berl) 89: 544-551
13. Jenkinson ML, Bliss MR, Brain AT, Scott DL (1989) Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br J Rheumatol 28: 86-88
14. Koh JY, Yang LL, Cotman CW (1990) Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 533: 315-320
15. Landfield PW, Eldridge JC (1989) Increased affinity of type II corticosteroid binding in aged rat hippocampus. Exp Neurol 106: 110-113
16. Lerea LS, McNamara JO (1993) Ionotropic glutamate receptor subtypes activate c-fos transcription by distinct calcium-requiring intracellular signaling pathways. Neuron 10: 31-41
17. Lewis DA, Smith RE (1983) Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord 5: 319-332
18. Marcusson J, Rother M, Kittner B, Rössner M, Smith J, Babic T, Folgenovic-Smalc V, Möller HJ, Labs KH (1997) A 12-month, randomized, plazebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM-III-R. Dement Geriatr Cogn Dis 8: 320-328
19. McGeer PL, Rogers J (1992) Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 42: 447-449
20. McGeer PL, McGeer E, Rogers J, Sibley J (1990) Anti-inflammatory drugs and Alzheimer disease. Lancet 335: 1037
21. McRae A, Rudolphi KA, Schubert P (1994) Propentofylline depresses amyloid and Alzheimer's CSF microglial antigens after ischaemia. Neuroreport 5: 1193-1196
22. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR (1993) Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90: 11693-11697
23. Morris JC, Edland S, Clark Ce (1993 43) The consortium to establish a registry for Alzheimer's Disease (CERAD), part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 43: 2457-2465
24. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45: 51-55
25. Rogers J, O'Barr S (1997) Inflammatory mediators in Alzheimer's disease. In: Wasco W, Tanzi RE (eds) Molecular mechanisms of dementia. Humana Press, Totowa New Jersey, pp 177-98
26. Rogers J, Luber Narod J, Styren SD, Civin WH (1988) Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging 9: 339-349
27. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson PL, et al (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology 43: 1609-1611
28. Vane J (1994) Towards a better aspirin. Nature 367: 215-216